Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CETIRIZINE HYDROCHLORIDE HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CETIRIZINE HYDROCHLORIDE HIVES.
BENYLIN vs CETIRIZINE HYDROCHLORIDE HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Selective inverse agonist of histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and gastrointestinal tract.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is approximately 8–11 hours in healthy adults (mean ~8.3 h). In renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 20–30 hours, requiring dose adjustment.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Approximately 70% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion, with about 10% excreted in feces. Biliary elimination is minimal.
Category C
Category A/B
Antihistamine
Antihistamine